Intervention Review

You have free access to this content

Complement inhibitors for age-related macular degeneration

  1. Michael A Williams1,*,
  2. Gareth J McKay2,
  3. Usha Chakravarthy3

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 15 JAN 2014

Assessed as up-to-date: 21 NOV 2013

DOI: 10.1002/14651858.CD009300.pub2


How to Cite

Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular degeneration. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD009300. DOI: 10.1002/14651858.CD009300.pub2.

Author Information

  1. 1

    Royal Victoria Hospital, Medical Ophthalmology, Eye and Ear Clinic, Belfast, Northern Ireland, UK

  2. 2

    Queen's University Belfast, Centre for Public Health, Belfast, Northern Ireland, UK

  3. 3

    Queen's University Belfast, Centre for Vision and Vascular Science, Belfast, Northern Ireland, UK

*Michael A Williams, Medical Ophthalmology, Eye and Ear Clinic, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland, BT12 6BA, UK. m.williams@qub.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 15 JAN 2014

SEARCH

References

References to ongoing studies

  1. References to ongoing studies
  2. Additional references
  3. References to other published versions of this review
NCT00935883 {published data only}
  • NCT00935883. Eculizumab for the treatment of non-exudative age-related macular degeneration: an exploratory study to evaluate the effects of C5 inhibition on drusen and geographic atrophy. clinicaltrials.gov/show/NCT00935883 (accessed 28 May 2013).
NCT00950638 {published data only}
  • NCT00950638. A phase I study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. clinicaltrials.gov/show/Nct00950638 (accessed 28 May 2013).

Additional references

  1. References to ongoing studies
  2. Additional references
  3. References to other published versions of this review
Anonymous 2009
  • Anonymous. Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration. Nature Reviews Drug Discovery 2009;8:922.
AREDS 2001
  • Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology 2001;119(10):1417-36.
Augood 2006
  • Augood CA, Vingerling JR, De Jong PT, Chakravarthy U, Seland J, Soubrane G, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Archives of Ophthalmology 2006;124(4):529-35.
Bora 2005
  • Bora PS, Sohn JH, Cruz JM, Jha P, Nishihori H, Wang Y, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. Journal of Immunology 2005;174(1):491-7.
Büttner-Mainik 2011
Chakravarthy 2010
  • Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010;10:31.
Crabb 2002
  • Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002;99(23):14682-7.
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
Despriet 2006
  • Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, De Maat MP, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296(3):301-9.
Edwards 2005
Evans 2004
  • Evans JR, Fletcher AE, Wormald RP. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: an add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology 2004;111(3):513-7.
Glanville 2006
  • Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
Hageman 2001
  • Hageman GS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Progress in Retinal and Eye Research 2001;20(6):705-32.
Hageman 2005
  • Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2005;102(20):7227-32.
Haines 2005
Haines 2007
  • Haines JL, Spencer KM, Pericak-Vance MA. Bringing the genetics of macular degeneration into focus. Proceedings of the National Academy of Sciences of the United States of America 2007;104(43):16725-6.
Heneka 2007
Higgins 2003
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
Hogg 2007
  • Hogg RE, Stevenson MR, Chakravarthy U, Beirne RO, Anderson RS. Early features of AMD. Ophthalmology 2007;114(5):1028.
Issa 2011
  • Issa CP, Chong NV, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefe's Archive for Clinical and Experimental Ophthalmology 2011;249(2):163-74.
Johnson 2000
Johnson 2002
  • Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11830-5.
Khandhadia 2012
Kirkham 2010
  • Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:365.
Klein 2005
Markiewski 2007
NCT00473928
  • Safety of intravitreal POT-4 therapy for patients with neovascular age-related macular degeneration. ClinicalTrials.gov/show/NCT00473928 (accessed 28 May 2013).
NCT00709527
  • ARC1905 (ANTI-C5 APTAMER) given either in combination therapy with Lucentis® 0.5 mg/eye in subjects with neovascular age-related macular degeneration. ClinicalTrials.gov/show/NCT00709527 (accessed 28 May 2013).
Owen 2003
  • Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. British Journal of Ophthalmology 2003;87(3):312-7.
Patel 2008
Review Manager 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Ricklin 2007
Riley 2011
Rodriguez 2004
  • Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Molecular Immunology 2004;41(4):355-67.
Schwartz 2011
  • Schwartz SG, Brantley MA, Jr. Pharmacogenetics and age-related macular degeneration. Journal of Ophthalmology 2011:Article ID 252549. [DOI: 10.1155/2011/252549]
Seddon 1997
Sivaprasad 2006
Sterne 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.
Tamamis 2012
Thornton 2005
Troutbeck 2012
www.alexionpharm.com/
  • www.alexionpharm.com/.
www.archemix.com/website/index.php
  • www.archemix.com/website/index.php.
www.ctt.upenn.edu/upstart.html
  • UPstart at the University of Pennsylvania. www.ctt.upenn.edu/upstart.html (accessed 24 May 2012).
www.jerini.com/cms/en/home.php
  • www.jerini.com/cms/en/home.php.
www.ophthotech.com/
  • www.ophthotech.com/.
www.potentiapharma.com/
  • www.potentiapharma.com/about/news.htm (accessed 13 May 2012).

References to other published versions of this review

  1. References to ongoing studies
  2. Additional references
  3. References to other published versions of this review
Williams 2011
  • Williams MA, McKay GJ, Chakravarthy U. Complement inhibitors for age-related macular degeneration. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD009300]